Twist Bioscience

Twist is the only commercial-scale DNA manufacturer running a silicon-chip synthesis platform, and in 2026 it is converting that infrastructure advantage into an inflecting financial story. Fiscal Q1 2026 delivered record revenue of $103.7M, and the company raised full-year fiscal 2026 guidance to $442–447M — roughly 16% year-over-year growth — while guiding to adjusted-EBITDA breakeven in the fourth quarter of fiscal 2026 with gross margin above 52%, a dramatic improvement from the sub-45% margins of prior years. That margin expansion is the thesis working: the highly automated "Factory of the Future" in Wilsonville, Oregon, which began shipping commercial product in 2023, is delivering the operating leverage a chip-based manufacturing platform was always supposed to produce. Twist's product breadth — synthetic genes and fragments, oligo pools, NGS library-prep and target-enrichment tools, and antibody-discovery libraries — makes it the default high-throughput supplier across synthetic biology, diagnostics, and drug discovery, a picks-and-shovels position that grows with the entire field regardless of which individual bio startups win. The longer-term DNA-data-storage program is embedded optionality on a potentially enormous archival-storage market. Public since 2018 (Nasdaq: TWST), Twist is a scaled, growing, margin-improving infrastructure company reaching the profitability threshold that separates durable franchises from cash-burning platforms.

Twist's path to breakeven has been long and expensive, and "adjusted EBITDA breakeven in Q4 of fiscal 2026" is still a forward promise, not a result — the company reported a roughly $13.4M adjusted-EBITDA loss in fiscal Q1 2026 and remains meaningfully unprofitable on a GAAP basis, so the market is pricing execution that has not yet fully landed. The core synthetic-gene business, though category-leading, sells into cyclical, budget-constrained end markets: academic, pharma, and biotech R&D spending contracts in downturns, and biotech funding has been under pressure, which caps how fast a supplier to the field can grow. Twist also faces intensifying competition in DNA synthesis, including enzymatic-synthesis entrants (DNA Script and others) promising benchtop, on-demand production that could eventually erode the centralized-manufacturing model Twist's silicon-chip factory is built around, and NGS-tools rivals with deeper franchises. The DNA-data-storage program remains pre-commercial and has been "years away" for years; it is optionality, not near-term value. Even at raised fiscal 2026 guidance, ~16% growth against the capital Twist has consumed and the market cap it carries demands sustained margin expansion and a genuine turn to cash generation — and a single guidance miss or macro-driven R&D pullback would reset a stock that has already been volatile. The infrastructure is impressive; the question is whether it earns durable profit before the next enzymatic-synthesis wave commoditizes the core.